[Federal Register Volume 61, Number 190 (Monday, September 30, 1996)]
[Notices]
[Page 51121]
From the Federal Register Online via the Government Publishing Office [www.gpo.gov]
[FR Doc No: 96-25023]
-----------------------------------------------------------------------
DEPARTMENT OF HEALTH AND HUMAN SERVICES
Prospective Grant of Exclusive License: Novel Method of O-
Demethylation and N-Deprotection of Opioid Compounds
AGENCY: National Institutes of Health, Public Health Service, DHHS.
ACTION: Notice.
-----------------------------------------------------------------------
SUMMARY: This is notice, in accordance with 35 U.S.C. 209(c)(1) and 37
CFR 404.7(a)(1)(i), that the National Institutes of Health (NIH),
Department of Health and Human Services, is contemplating the grant of
an exclusive license in the United States to practice the invention
embodied in: U.S. Patent Application Serial No. 60/018,027, filed May
21, 1996, entitled, ``Novel Method of O-Demethylation of Opium
Alkaloids and Derivatives''; and U.S. Patent Application Serial No. 60/
020,215, filed June 21, 1996, entitled, ``Novel Method of O-
Demethylation and N-Deprotection of Opioid Compounds''; to Mallinckrodt
Chemical, Inc., having a place of business in Chesterfield, Missouri.
The patent rights in these inventions have been assigned to the United
States of America.
The patents and patent applications claim improvements to the
synthesis method for synthetic medicinal opiates that produce high
yields. O-demethylation and N-deprotection are key steps in the
synthesis of opioid compounds. The methods of these inventions
accomplish these procedures without the use of toxic or carcinogenic
reagents.
The prospective exclusive license will be royalty-bearing and will
comply with the terms and conditions of 35 U.S.C. 209 and 37 CFR 404.7.
The prospective exclusive license may be granted unless, within 90 days
from the date of this published Notice, NIH receives written evidence
and argument that establishes that the grant of the license would not
be consistent with the requirements of 35 U.S.C. 209 and 37 CFR 404.7.
ADDRESSES: Requests for a copy of the patent applications, inquiries,
comments and other materials relating to the contemplated license
should be directed to: Leopold J. Luberecki, Jr., J.D., Technology
Licensing Specialist, Office of Technology Transfer, National
Institutes of Health, 6011 Executive Boulevard, Box 13, Rockville, MD
20852-3804. Telephone: (301) 496-7735, ext. 223; Facsimile: (301) 402-
0220. Properly filed competing applications for a license filed in
response to this notice will be treated as objections to the
contemplated license. Only written comments and/or application for a
license which are received by the NIH Office of Technology Transfer on
or before December 30, 1996 will be considered.
Comments and objections submitted in response to this notice will
not be made available for public inspection, and, to the extent
permitted by law, will not be released under the Freedom of Information
Act, 5 U.S.C. 552.
Dated: September 9, 1996.
Barbara M. McGarey,
Deputy Director, Office of Technology Transfer.
[FR Doc. 96-25023 Filed 9-27-96; 8:45 am]
BILLING CODE 4140-01-M
